Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Lessons in human biology from a monogenic pancreatic β cell disease
Benjamin Glaser
Benjamin Glaser
Published September 26, 2011
Citation Information: J Clin Invest. 2011;121(10):3821-3825. https://doi.org/10.1172/JCI60002.
View: Text | PDF
Commentary

Lessons in human biology from a monogenic pancreatic β cell disease

  • Text
  • PDF
Abstract

Deciphering the complexities of human β cell physiology is critical to our understanding of the pathophysiology behind both type 1 and type 2 diabetes. One way to do this is to study individuals with congenital hyperinsulinism (CHI), a rare genetic disease characterized by dysregulation of insulin secretion resulting in hypoglycemia. In this issue of the JCI, Henquin et al. report in vitro studies of pancreatic tissue obtained from CHI patients during therapeutic pancreatectomy that have yielded exciting new insights into human β cell physiology. The data validate and extend observations made in model organisms.

Authors

Benjamin Glaser

×

Figure 1

Schematic representation of the major genetic etiologies of CHI.

Options: View larger image (or click on image) Download as PowerPoint
Schematic representation of the major genetic etiologies of CHI.
Some of...
Some of the major pathways regulating insulin secretion are shown. The proteins encoded by genes mutated in different forms of CHI are shown in red. Mutations in either ABCC8 (which encodes SUR1) or KCNJ11 (which encodes Kir6.2) result in defective KATP channel activity and continuous membrane depolarization regardless of glucose levels. Activating mutations in glucokinase (GCK) result in increased glucose metabolism at low circulating glucose levels, resulting in a decreased threshold for glucose-stimulated insulin secretion and thus inappropriate insulin secretion in the presence of hypoglycemia (18). Glutamate dehydrogenase 1 (GLUD1) mutations result in increased conversion of glutamate to α-ketoglutarate (αKG), thereby increasing ATP production and insulin secretion (19). Solute carrier family 16, member 1 (SLC16A1) promoter mutations result in inappropriate expression of this transporter in β cells, allowing pyruvate and lactate to enter the cell. Pyruvate can then enter the Krebs cycle, thus increasing ATP production and insulin secretion. Patients with mutations in this gene have a unique form of CHI characterized by exercise-induced hypoglycemia (20). Inactivating mutations in hydroxyacyl-CoA dehydrogenase (HADH) also cause CHI and have been shown to do so by regulating insulin secretion in a KATP channel–independent fashion (21) and by preventing HADH-mediated inhibition of GLUD1 in the β cell (22). Glucagon-like peptide 1 (GLP1), glucose-dependent insulinotrophic peptide (GIP), glucagon, somatostatin, and other signals not shown in this simplified diagram regulate critical amplifying pathways downstream from the CHI-related proteins.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts